Scribe Therapeutics converting an Alameda shipway into a lab
The Real Deal
|
July 30, 2022
X min read
The Real Deal
|
July 30, 2022
Share on Social
More like this
News
Scribe Therapeutics Projected to Enter the Clinic in Mid-2026 with STX-1150, a PCSK9-targeting CRISPR Epigenetic Silencing Therapy for Durable LDL-C Reduction
January 20, 2026
Read Now
Press
Scribe Therapeutics Projected to Enter the Clinic in Mid-2026 with STX-1150, a PCSK9-targeting CRISPR Epigenetic Silencing Therapy for Durable LDL-C Reduction
January 20, 2026
Read Now
